A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Idelalisib (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 12 Dec 2017 Results (n=853) of ad hoc analysis assessing rates of grade more than or equal to 3 transaminase elevation using patient data from this and other 5 trials presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results of the validated risk model for Overall survival in CLL patients from five randomised trials (HELIOS, RESONATE, Study 115, Study 116 and Study 119; n=1866) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2016 Results assessing outcomes presented of patients with Complex Karyotype (n=127) at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top